Statins in lymphangioleiomyomatosis: a word of caution.
作者信息
El-Chemaly S, Taveira-DaSilva A, Stylianou M P, Moss J
出版信息
Eur Respir J. 2009 Aug;34(2):513-4. doi: 10.1183/09031936.00012709.
Abstract
摘要
相似文献
1
Statins in lymphangioleiomyomatosis: a word of caution.淋巴管平滑肌瘤病中他汀类药物的应用：需谨慎对待
Eur Respir J. 2009 Aug;34(2):513-4. doi: 10.1183/09031936.00012709.
2
Lymphangioleiomyomatosis: New Treatment Perspectives.淋巴管平滑肌瘤病：新的治疗前景
Lung. 2015 Aug;193(4):467-75. doi: 10.1007/s00408-015-9742-6. Epub 2015 May 17.
3
Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).预防肺淋巴管平滑肌瘤病（LAM）小鼠模型中的肺泡破坏和气腔扩大。
Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.
4
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.结节性硬化症模型Tsc2(+/-)小鼠的肾肿瘤和肝肿瘤对3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂阿托伐他汀治疗无反应。
Mol Cancer Ther. 2009 Jul;8(7):1799-807. doi: 10.1158/1535-7163.MCT-09-0055. Epub 2009 Jul 7.
5
Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.在淋巴管平滑肌瘤病小鼠模型中，用阿昔替尼对VEGFR信号进行药理学靶向可抑制Tsc2基因缺失病变的生长。
Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.
6
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.他汀类药物在淋巴管平滑肌瘤病中的作用。辛伐他汀和阿托伐他汀对结节性硬化症复合物 2 缺失细胞的生长和信号转导有不同的影响。
Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.
7
Treatment of the pulmonary involvement in the patient with tuberous sclerosis complex.结节性硬化症患者肺部受累的治疗。
Contrib Nephrol. 2001(136):292-8. doi: 10.1159/000060204.
8
Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.肺淋巴管平滑肌瘤病（LAM）：进展与当前挑战
J Cell Biochem. 2008 Feb 1;103(2):369-82. doi: 10.1002/jcb.21419.
9
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.异常的SYK激酶信号传导对于TSC2失活诱导的肿瘤发生至关重要。
Cancer Res. 2017 Mar 15;77(6):1492-1502. doi: 10.1158/0008-5472.CAN-16-2755. Epub 2017 Feb 15.
10
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.尿激酶型纤溶酶原激活剂（uPA）对于结节性硬化症复合物2（TSC2）缺陷型肿瘤的进展至关重要。
J Biol Chem. 2017 Dec 15;292(50):20528-20543. doi: 10.1074/jbc.M117.799593. Epub 2017 Sep 27.
引用本文的文献
1
Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy.对柳泽的回复：孕期肺淋巴管平滑肌瘤病的治疗
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1507-1508. doi: 10.1164/rccm.201801-0043LE.
2
Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).治疗肺淋巴管平滑肌瘤病（LAM）的治疗策略
Expert Opin Orphan Drugs. 2014 Oct 1;2(10):1063-1074. doi: 10.1517/21678707.2014.953481. Epub 2014 Aug 27.
3
Lymphangioleiomyomatosis: New Treatment Perspectives.淋巴管平滑肌瘤病：新的治疗前景
Lung. 2015 Aug;193(4):467-75. doi: 10.1007/s00408-015-9742-6. Epub 2015 May 17.
4
Management of lymphangioleiomyomatosis.淋巴管平滑肌瘤病的管理
F1000Prime Rep. 2014 Dec 1;6:116. doi: 10.12703/P6-116. eCollection 2014.
5
Lymphangioleiomyomatosis: differential diagnosis and optimal management.淋巴管平滑肌瘤病：鉴别诊断与最佳治疗。
Ther Clin Risk Manag. 2014 Aug 21;10:691-700. doi: 10.2147/TCRM.S50784. eCollection 2014.
6
Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.西罗莫司与辛伐他汀联合治疗淋巴管平滑肌瘤病的回顾性研究
Chest. 2015 Jan;147(1):180-187. doi: 10.1378/chest.14-0758.
7
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.他汀类药物在淋巴管平滑肌瘤病中的作用。辛伐他汀和阿托伐他汀对结节性硬化症复合物 2 缺失细胞的生长和信号转导有不同的影响。
Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.
8
Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).针对肺淋巴管平滑肌瘤病（LAM）的理解和治疗的靶向方法。
Horm Cancer. 2013 Apr;4(2):70-7. doi: 10.1007/s12672-012-0128-4. Epub 2012 Nov 27.
9
Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).预防肺淋巴管平滑肌瘤病（LAM）小鼠模型中的肺泡破坏和气腔扩大。
Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.
10
Optimizing treatments for lymphangioleiomyomatosis.优化淋巴管平滑肌瘤病的治疗方法。
Expert Rev Respir Med. 2012 Jun;6(3):267-76. doi: 10.1586/ers.12.26.
本文引用的文献
1
Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.他汀类药物与间质性肺病：文献及美国食品药品监督管理局不良事件报告的系统评价
Chest. 2008 Oct;134(4):824-830. doi: 10.1378/chest.08-0943. Epub 2008 Aug 8.
2
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.西罗莫司用于治疗结节性硬化症或淋巴管平滑肌瘤病中的肾血管平滑肌脂肪瘤。
N Engl J Med. 2008 Jan 10;358(2):140-51. doi: 10.1056/NEJMoa063564.
3
Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.阿托伐他汀对结节性硬化复合物2缺失细胞生长的选择性抑制与Rheb和Rho GTP酶功能受损以及mTOR/S6激酶活性降低有关。
Cancer Res. 2007 Oct 15;67(20):9878-86. doi: 10.1158/0008-5472.CAN-07-1394.
4
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.强力霉素治疗淋巴管平滑肌瘤病并对基质金属蛋白酶进行尿液监测。
N Engl J Med. 2006 Jun 15;354(24):2621-2. doi: 10.1056/NEJMc053410.
5
Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin.人微血管内皮细胞的血管生成转录组：缺氧的影响及阿托伐他汀的调节作用
Vascul Pharmacol. 2006 Apr;44(4):206-14. doi: 10.1016/j.vph.2005.11.007. Epub 2006 Feb 14.
6
Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.接受或未接受孕酮治疗的淋巴管平滑肌瘤病患者的肺功能下降。
Chest. 2004 Dec;126(6):1867-74. doi: 10.1378/chest.126.6.1867.
Zotero 插件